Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $4.6 million.

  • Gyre Therapeutics' Cash from Operations rose 16854.0% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 5652.0%. This contributed to the annual value of -$3.6 million for FY2024, which is 11406.23% down from last year.
  • Gyre Therapeutics' Cash from Operations amounted to $4.6 million in Q3 2025, which was up 16854.0% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Cash from Operations peaked at $42.3 million during Q4 2022, and registered a low of -$24.4 million during Q1 2021.
  • In the last 5 years, Gyre Therapeutics' Cash from Operations had a median value of -$129000.0 in 2025 and averaged -$2.3 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 40847.6% in 2021, then soared by 33929.62% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Cash from Operations (Quarter) stood at -$17.7 million in 2021, then skyrocketed by 339.3% to $42.3 million in 2022, then plummeted by 92.06% to $3.4 million in 2023, then tumbled by 182.08% to -$2.8 million in 2024, then soared by 268.06% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q3 2025, $2.1 million for Q2 2025, and -$129000.0 during Q1 2025.